Amgen Tops Q2 Forecasts, Lifts Outlook; Pipeline Gains Offset by TAVNEOS Uncertainty
AMGN sits 45% above its 52-week low of $269.77.
Summary
Amgen reported Q2 2026 revenue of $10.1B and non-GAAP EPS of $6.29, beating estimates, and raised full-year guidance. The pipeline update featured progress in obesity and oncology, but TAVNEOS regulatory risk remains.
Updates
· SEC 10-Q — 10-Q discloses TAVNEOS developed-product-technology rights carrying value of $2.4 billion as of June 30, 2026, with $2.3 billion related to the U.S. market.
Key Events · Earnings and Guidance · AMGN
-
Q2 Earnings Beat
Total revenues of $10.1B (+10% YoY) and non-GAAP EPS of $6.29 beat consensus estimates of $5.62. GAAP EPS was $4.37, up 65% YoY.
-
Raised Full-Year Guidance
2026 revenue guidance raised to $38.2B-$39.4B; non-GAAP EPS guidance raised to $22.30-$23.50, reflecting confidence in growth drivers.
-
Free Cash Flow Surge
Free cash flow reached $3.5B in Q2, up from $1.9B a year ago, driven by business performance and lapping of a repatriation tax payment.
-
Pipeline Progress and Setbacks
MariTide obesity program advancing with multiple Phase 3 trials; AMG 513 discontinued; subcutaneous blinatumomab studies on partial clinical hold.
Analysis · AMGN · Life Sciences
A strong second quarter saw Amgen surpass consensus with revenue of $10.1B and non-GAAP EPS of $6.29. The company raised its full-year revenue and EPS guidance, underscoring confidence in its growth trajectory. Free cash flow surged to $3.5B, providing ample capital for pipeline investment. However, the ongoing TAVNEOS regulatory saga and a recent cybersecurity breach add risk. The pipeline update highlights MariTide's broad Phase 3 program in obesity, but the discontinuation of AMG 513 and a partial clinical hold on subcutaneous blinatumomab are setbacks. Overall, the earnings beat and raised guidance are positive, but the stock is near its 52-week high, and the TAVNEOS overhang persists.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMGN was trading at $392.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.5B. The 52-week trading range was $269.77 to $398.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.